Chemex Pharmaceuticals Inc. of Fort Lee, N.J., has completedPhase I safety studies for EPC-K1, a topical, non-steroidal anti-inflammatory compound, patented and licensed from SenjuPharmaceuticals, under a joint venture with Block Drug Co. Inc.
The study established safety and anti-inflammatory activity intopical use in people. An additional pilot study to establishefficacy for the treatment of seborrheic dermatitis should startthis fall prior to Phase II trials in the fourth quarter.
(c) 1997 American Health Consultants. All rights reserved.